Key Points
- Insider selling: Pharvaris insider Wim Souverijns sold 20,000 shares for approximately $786,200, reducing his ownership by 30.72% to 45,111 shares. He also sold 6,090 shares the following day.
- Stock and earnings: PHVS opened at $37.55, with a market capitalization of about $2.46 billion, while its latest quarterly loss of $0.81 per share missed analyst expectations of $0.75.
- Analyst outlook remains positive: Analysts maintain a “Moderate Buy” consensus, with a consensus price target near $60 and recent targets ranging from $60 to $75, supported by encouraging phase III results for lead drug candidate deucrictibant.
Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) insider Wim Souverijns sold 6,090 shares of Pharvaris stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $38.99, for a total transaction of $237,449.10. Following the transaction, the insider owned 39,021 shares of the company's stock, valued at approximately $1,521,428.79. The trade was a 13.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Wim Souverijns also recently made the following trade(s):
- On Monday, September 14th, Wim Souverijns sold 20,000 shares of Pharvaris stock. The stock was sold at an average price of $39.31, for a total value of $786,200.00.
Pharvaris Stock Performance
PHVS stock opened at $37.55 on Thursday. The stock's 50 day moving average price is $35.31 and its 200 day moving average price is $31.63. The firm has a market cap of $2.46 billion, a P/E ratio of -12.31 and a beta of -2.33. Pharvaris N.V. has a 1 year low of $20.65 and a 1 year high of $43.25.
Pharvaris (NASDAQ:PHVS - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). On average, research analysts predict that Pharvaris N.V. will post -3.12 earnings per share for the current year.
Institutional Trading of Pharvaris
Institutional investors have recently made changes to their positions in the stock. Quantbot Technologies LP purchased a new stake in shares of Pharvaris in the second quarter worth about $41,000. CoreCap Advisors LLC purchased a new position in Pharvaris in the 2nd quarter valued at about $93,000. Amundi grew its stake in shares of Pharvaris by 12.0% during the first quarter. Amundi now owns 30,952 shares of the company's stock valued at $874,000 after acquiring an additional 3,312 shares in the last quarter. Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Pharvaris during the fourth quarter valued at about $139,000. Finally, Sofinnova Investments Inc. increased its position in shares of Pharvaris by 0.7% during the fourth quarter. Sofinnova Investments Inc. now owns 745,169 shares of the company's stock worth $20,678,000 after acquiring an additional 5,293 shares during the last quarter.
Analyst Upgrades and Downgrades
Several research firms have issued reports on PHVS. Leerink Partners raised their price target on shares of Pharvaris from $50.00 to $65.00 and gave the stock an "outperform" rating in a research note on Wednesday, September 9th. UBS Group set a $79.00 target price on shares of Pharvaris in a research note on Wednesday, September 9th. Wedbush boosted their price target on Pharvaris from $42.00 to $50.00 and gave the company an "outperform" rating in a report on Wednesday, September 9th. Morgan Stanley increased their price target on Pharvaris from $46.00 to $62.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 9th. Finally, Citigroup reaffirmed a "market outperform" rating on shares of Pharvaris in a research report on Wednesday, September 9th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $59.87.
Check Out Our Latest Stock Analysis on PHVS
Key Stories Impacting Pharvaris
Here are the key news stories impacting Pharvaris this week:
- Positive Sentiment: Pharvaris’ phase III data showed that once-daily extended-release deucrictibant reduced hereditary angioedema attacks by 83%. The result strengthens the case for the company’s lead drug and supports planned regulatory submissions in 2027. PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
- Positive Sentiment: Analyst expectations remain favorable. The reported consensus price target rose 20.08% to $59.77, while recent targets include $62 from RBC and $65 from Wells Fargo and Leerink Partners. The broader analyst consensus is “Moderate Buy.” Pharvaris Consensus Price Target Raised
- Positive Sentiment: Recent institutional activity has been supportive, including a new BlackRock position and larger holdings from Alyeska Investment Group and Seven Fleet Capital, suggesting increased professional-investor interest.
- Neutral Sentiment: Pharvaris presented at the Morgan Stanley 24th Annual Global Healthcare Conference. The event provided management with an opportunity to discuss deucrictibant and its regulatory strategy, but the supplied transcript does not identify a separate new announcement. Pharvaris Morgan Stanley Conference Transcript
- Negative Sentiment: Insider selling is weighing on sentiment. Insider Wim Souverijns sold 26,090 shares for approximately $1.02 million across September 14–15, while CEO Berndt Modig sold 2,291 shares worth about $90,265. President Peng Lu also sold 15,000 shares for roughly $602,000 to cover tax withholding related to vested equity awards. Anne Lesage separately sold 30,000 shares for approximately $1.15 million. Although some sales were tax-related and insiders retain significant holdings, the volume of selling can raise concerns about near-term supply and insider confidence. Pharvaris Insider Selling
Pharvaris Company Profile
(
Get Free Report)
Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.
Pharvaris' lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
